QuantHealth, an AI-based clinical trial design company, has announced it has surpassed 100 successfully simulated clinical trials, achieving 85% accuracy and a major return on investment (ROI) for pharmaceutical partners. This achievement underscores the potential of AI to revolutionize drug development and reduce the high failure rate of clinical trials.
Addressing Clinical Trial Failures with AI
Historically, 90% of clinical trials fail due to suboptimal protocol design, inefficiencies, and safety concerns. With drug development taking 10 to 15 years and costing nearly $1 billion per drug, most candidates fail to reach approval. QuantHealth's Clinical-Simulator addresses these challenges by forecasting individual patient responses within clinical trials, empowering design teams to anticipate overall trial dynamics and adjust strategies accordingly.
Financial Returns and Improved Trial Success
In partnership with one pharmaceutical company’s respiratory disease team, QuantHealth enabled cost reductions of more than $215 million and significantly improved the likelihood of trial success. Utilizing data from 350 million patients and 700,000 drug entities, its advanced analytics module simulated over 5,000 protocol variations within minutes to identify which factors most likely contributed to success. The AI platform identified the protocol with the highest odds of technical success from over 30 positive protocols.
This process reduced study duration by 11 months, clinical trial subjects by 251, and full-time employees by 1.5 individuals, resulting in financial returns of $15 million, $200 million, and $385,000, respectively.
Accuracy Outcomes Exceed National Averages
QuantHealth’s accuracy outcomes exceeded national averages for Phase II and III trials, highlighting the power of AI-generated clinical trials. For example, Oncology rates were 58.3% better (88% compared to the national rate of 29.7%), Immune & Inflammation rates were 37.8% better (80% compared to the national rate of 42.2%), Gastroenterology rates were 41.4% better (83% compared to the national rate of 41.6%), and Respiratory rates were 52.6% better (84% compared to the national rate of 31.4%).
Phase 2 rates were 59.1% better (88% compared to the national rate of 28.9%), and Phase 3 rates were 25.4% better (83.2% compared to the national rate of 57.8%).
Industry Impact and Future Outlook
"Being at the forefront of AI-enabled clinical trials for nearly a decade, it’s astounding to see how much progress has been made and the promise that AI holds for clinical trial improvement," said Orr Inbar, CEO and Co-Founder of QuantHealth. "Once seen as science fiction, our technology has proven to safely and accurately predict the results of clinical trials and now has significant traction. We currently have five of the top 20 pharmaceutical companies on board, and with this number expected to double by next year, we look forward to addressing the core issue of trial failures at scale, and continuing to meet market needs swiftly and effectively."
